Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

OSCRBullishResearch Analysisnews

High materiality8/10

Oscar Health lifts 2026 guidance; analysts raise price targets

Sep 17, 2026, 12:48 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Fresh earnings guidance upgrades and higher price targets indicate durable profitability improvement and potential multiple expansion, especially with strong pre-market momentum and OSCR trading near the 52-week high.

AI summary

What happened, with direct paths to the underlying reporting

Oscar Health raised its 2026 EOP by $100m to $600–$800m, improved MLR to 81.0–82.0%, and reaffirmed revenue guidance of $18.7–$19.0b, triggering fresh price targets from Barclays, Baird and Stephens. OSCR rose about 2.4% in early trading and sits near a 52-week high around $34.47, signaling potential near-term upside.

OSCR gains after 2026 guidance upgrade; analysts lift targets.
2026 EOP target raised to $600–$800m; MLR narrowed to 81.0–82.0%.
Revenue guidance kept at $18.7–$19.0b; SG&A 15.6–16.1%.
Barclays target raised to $49; peers to $33–$34.
Stock near 52-week high at $34.47.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.